Company news
Precigen, Inc. news in 2026
Precigen, Inc.'s news releases, calls and decks from 2026, newest first.
Precigen to Announce Third Quarter 2026 Financial Results and Provide Business Updates on November 4
October 28, 2026
Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform
September 21, 2026
Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth
August 4, 2026
Precigen to Announce Second Quarter 2026 Financial Results and Provide Business Updates on August 4
July 21, 2026
Precigen Gains Advantage as PAPZIMEOS Granted Orphan Drug Exclusivity by FDA; Long-Term Data From Clinical Study Encouraging
June 14, 2026
Precigen and the Recurrent Respiratory Papillomatosis Foundation Recognize International RRP Awareness Day by Elevating Patient and Community Voices
June 11, 2026
Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years
May 30, 2026
Precigen Receives Orphan Drug Exclusivity for PAPZIMEOS (zopapogene imadenovec-drba) in the United States
May 26, 2026
Precigen to Participate in Fireside Chats with J.P. Morgan and at the Goldman Sachs 47th Annual Global Healthcare Conference
May 26, 2026
Precigen Reports First Quarter 2026 Financial Results and Business Updates
May 13, 2026
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
May 7, 2026
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
March 29, 2026
Precigen Reports Full Year 2025 Financial Results and Business Updates
March 24, 2026
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
March 10, 2026
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
January 20, 2026
Precigen Showcases Rapid Commercialization Momentum and Growing Market Adoption of First-and-Only FDA-Approved Therapy for RRP at the 44th Annual J.P. Morgan Healthcare Conference
January 11, 2026
Precigen to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 4, 2026
Calls in 2026
Decks in 2026
- Q1 2026 Earnings Presentation
Earnings · 21 slides · May 13, 2026